These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 36228755)

  • 21. Ternary Dry Powder Agglomerate Inhalation Formulation of Melatonin With Air Jet Mixing to Improve In Vitro And In Vivo Performance.
    Zhang Q; Kou S; Cui Y; Dong J; Ye Y; Wang Y; Lu R; Li X; Nie Y; Shi K; Chen F; Hall P; Chen X; Wang Z; Jiang X
    J Pharm Sci; 2024 Feb; 113(2):434-444. PubMed ID: 37995838
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preparation of dry powder inhalation with lactose carrier particles surface-coated using a Wurster fluidized bed.
    Iida K; Todo H; Okamoto H; Danjo K; Leuenberger H
    Chem Pharm Bull (Tokyo); 2005 Apr; 53(4):431-4. PubMed ID: 15802846
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Protein deposition from dry powder inhalers: fine particle multiplets as performance modifiers.
    Lucas P; Anderson K; Staniforth JN
    Pharm Res; 1998 Apr; 15(4):562-9. PubMed ID: 9587952
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Improved respirable fraction of budesonide powder for dry powder inhaler formulations produced by advanced supercritical CO
    Miyazaki Y; Aruga N; Kadota K; Tozuka Y; Takeuchi H
    Int J Pharm; 2017 Aug; 528(1-2):118-126. PubMed ID: 28583335
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lactose modifications enhance its drug performance in the novel multiple dose Taifun DPI.
    Harjunen P; Lehto VP; Martimo K; Suihko E; Lankinen T; Paronen P; Järvinen K
    Eur J Pharm Sci; 2002 Sep; 16(4-5):313-21. PubMed ID: 12208462
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Effect of mixing of fine carrier particles on dry powder inhalation property of salbutamol sulfate (SS)].
    Iida K; Leuenberger H; Fueg LM; Müller-Walz R; Okamoto H; Danjo K
    Yakugaku Zasshi; 2000 Jan; 120(1):113-9. PubMed ID: 10655787
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of surface covering of lactose carrier particles on dry powder inhalation properties of salbutamol sulfate.
    Iida K; Hayakawa Y; Okamoto H; Danjo K; Luenbergerb H
    Chem Pharm Bull (Tokyo); 2003 Dec; 51(12):1455-7. PubMed ID: 14646332
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of SCF-engineered particle-based lactose blends in passive dry powder inhalers.
    Schiavone H; Palakodaty S; Clark A; York P; Tzannis ST
    Int J Pharm; 2004 Aug; 281(1-2):55-66. PubMed ID: 15288343
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recent developments in lactose blend formulations for carrier-based dry powder inhalation.
    Hebbink GA; Jaspers M; Peters HJW; Dickhoff BHJ
    Adv Drug Deliv Rev; 2022 Oct; 189():114527. PubMed ID: 36070848
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of the screw profile on granular structure and mixing efficiency of a high-dose hydrophobic drug formulation during twin screw wet granulation.
    Kashani Rahimi S; Paul S; Sun CC; Zhang F
    Int J Pharm; 2020 Feb; 575():118958. PubMed ID: 31846725
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A New Role of Fine Excipient Materials in Carrier-Based Dry Powder Inhalation Mixtures: Effect on Deagglomeration of Drug Particles During Mixing Revealed.
    Shalash AO; Elsayed MMA
    AAPS PharmSciTech; 2017 Nov; 18(8):2862-2870. PubMed ID: 28421352
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Spray dried powders and powder blends of recombinant human deoxyribonuclease (rhDNase) for aerosol delivery.
    Chan HK; Clark A; Gonda I; Mumenthaler M; Hsu C
    Pharm Res; 1997 Apr; 14(4):431-7. PubMed ID: 9144727
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pulmonary deposition of lactose carriers used in inhalation powders.
    Karhu M; Kuikka J; Kauppinen T; Bergström K; Vidgren M
    Int J Pharm; 2000 Feb; 196(1):95-103. PubMed ID: 10675711
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Co-milled API-lactose systems for inhalation therapy: impact of magnesium stearate on physico-chemical stability and aerosolization performance.
    Lau M; Young PM; Traini D
    Drug Dev Ind Pharm; 2017 Jun; 43(6):980-988. PubMed ID: 28122460
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of flow properties of dry powder inhalation of salbutamol sulfate with lactose carrier.
    Iida K; Hayakawa Y; Okamoto H; Danjo K; Leuenberger H
    Chem Pharm Bull (Tokyo); 2001 Oct; 49(10):1326-30. PubMed ID: 11605663
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The influence of high shear mixing on ternary dry powder inhaler formulations.
    Hertel M; Schwarz E; Kobler M; Hauptstein S; Steckel H; Scherließ R
    Int J Pharm; 2017 Dec; 534(1-2):242-250. PubMed ID: 29051120
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of HPMC Inhalation-Grade Capsules and Their Effect on Aerosol Performance Using Budesonide and Rifampicin DPI Formulations.
    Ding L; Brunaugh AD; Thakkar R; Lee C; Zhao QJ; Kalafat J; Maniruzzaman M; Smyth HDC
    AAPS PharmSciTech; 2022 Jan; 23(1):52. PubMed ID: 35018574
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhalable co-amorphous budesonide-arginine dry powders prepared by spray drying.
    Lu W; Rades T; Rantanen J; Yang M
    Int J Pharm; 2019 Jun; 565():1-8. PubMed ID: 30999050
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dry powders for inhalation containing monoclonal antibodies made by thin-film freeze-drying.
    Hufnagel S; Xu H; Sahakijpijarn S; Moon C; Chow LQM; Williams Iii RO; Cui Z
    Int J Pharm; 2022 Apr; 618():121637. PubMed ID: 35259440
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Co-spray dried hydrophobic drug formulations with crystalline lactose for inhalation aerosol delivery.
    Ke WR; Kwok PCL; Khanal D; Chang RYK; Chan HK
    Int J Pharm; 2021 Jun; 602():120608. PubMed ID: 33862136
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.